CN100475212C - 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 - Google Patents

用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 Download PDF

Info

Publication number
CN100475212C
CN100475212C CNB2003801031558A CN200380103155A CN100475212C CN 100475212 C CN100475212 C CN 100475212C CN B2003801031558 A CNB2003801031558 A CN B2003801031558A CN 200380103155 A CN200380103155 A CN 200380103155A CN 100475212 C CN100475212 C CN 100475212C
Authority
CN
China
Prior art keywords
combination
compound
treatment
chronic lymphocytic
chlorambucil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801031558A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711090A (zh
Inventor
劳伦斯·卡尔·帕纳西
拉克尔·希尔维阿·阿洛奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jewish General Hospital
Original Assignee
Jewish General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jewish General Hospital filed Critical Jewish General Hospital
Publication of CN1711090A publication Critical patent/CN1711090A/zh
Application granted granted Critical
Publication of CN100475212C publication Critical patent/CN100475212C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CNB2003801031558A 2002-11-12 2003-11-10 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 Expired - Fee Related CN100475212C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42548102P 2002-11-12 2002-11-12
US60/425,481 2002-11-12

Publications (2)

Publication Number Publication Date
CN1711090A CN1711090A (zh) 2005-12-21
CN100475212C true CN100475212C (zh) 2009-04-08

Family

ID=32312996

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801031558A Expired - Fee Related CN100475212C (zh) 2002-11-12 2003-11-10 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合

Country Status (11)

Country Link
US (2) US20060122186A1 (enExample)
EP (1) EP1578426B1 (enExample)
JP (1) JP4854198B2 (enExample)
CN (1) CN100475212C (enExample)
AT (1) ATE468855T1 (enExample)
AU (1) AU2003280191A1 (enExample)
BR (1) BR0316126A (enExample)
CA (1) CA2504665C (enExample)
DE (1) DE60332762D1 (enExample)
ES (1) ES2348140T3 (enExample)
WO (1) WO2004043466A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
US8501817B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
EP2240172B1 (en) * 2007-12-21 2014-03-19 Novartis AG Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
CN105492011A (zh) * 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
CN105997981A (zh) * 2016-06-13 2016-10-12 崔坤峰 苯丁酸氮芥的药物组合物及其抗抑郁的医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088777A (zh) * 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
WO2003094904A1 (en) * 2002-05-13 2003-11-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088777A (zh) * 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STI571联合化疗或造血干细胞移植治疗慢性粒细胞白血病. 武文等.广东医学，第23卷第9期. 2002 *

Also Published As

Publication number Publication date
US20060122186A1 (en) 2006-06-08
US20090312290A1 (en) 2009-12-17
US8492383B2 (en) 2013-07-23
BR0316126A (pt) 2005-09-27
JP4854198B2 (ja) 2012-01-18
ES2348140T3 (es) 2010-11-30
AU2003280191A1 (en) 2004-06-03
EP1578426A1 (en) 2005-09-28
CA2504665C (en) 2012-12-18
ATE468855T1 (de) 2010-06-15
CN1711090A (zh) 2005-12-21
EP1578426B1 (en) 2010-05-26
WO2004043466A1 (en) 2004-05-27
JP2006508118A (ja) 2006-03-09
CA2504665A1 (en) 2004-05-27
DE60332762D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
US8492383B2 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
MXPA04010496A (es) Tableta con alta carga de farmaco.
US20240197743A1 (en) Wee1 compound for treating uterine serous carcinoma
JPH08508045A (ja) 癌性疾患の予防および治療のための製剤組成物、ならびにその製造法
EP4585269A2 (en) Methods for cancer therapy
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
JP7113826B2 (ja) プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
EP4197539A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
EP4095137A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
JP7332589B2 (ja) 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
JP2006508118A5 (enExample)
UA76254C2 (en) Use of desoxypeganine for treating clinical depression
JP2024513260A (ja) 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ
JP2017226668A (ja) トロンボポエチンアゴニスト化合物の投与の方法
US20050159426A1 (en) Treatment of neuroblastoma
CA3223692A1 (en) Erk1/2 inhibitor combination therapy
NZ788615B2 (en) Dosing of a bruton's tyrosine kinase inhibitor
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
JP2025538876A (ja) がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090408

Termination date: 20141110

EXPY Termination of patent right or utility model